Ligand Pharma (LGND) Announces EU Approval of DUAVIVE as Estrogen Deficiency Treatment (PFE)
Tweet Send to a Friend
Ligand Pharma (NASDAQ: LGND) announced that its partner Pfizer (NYSE: PFE) has received EU marketing authorization for DUAVIVE (conjugated estrogens/bazedoxifene ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE